Pfizer has entered into an agreement to acquire ReViral Ltd, a portfolio company of life sciences investor Novo Holdings. The deal could reach up to $525 million in value. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals.

ReViral is a London-based biopharmaceutical company specializing in antiviral therapeutics. The firm has developed promising therapeutic treatments for RSV, a respiratory pathogen that targets high-risk populations. Novo Ventures, the venture capital wing of Nova Holdings, first invested in ReViral in 2018 co-leading a $55 million Series B financing.

“The proposed acquisition of the Company by Pfizer confirms the promise of ReViral’s pipeline of novel RSV therapeutics,” said Naveed Siddiqi, the board director of ReViral and senior partner at Novo Holdings. As a leading transatlantic investor, Novo Holdings has a 20-year record of backing and supporting experienced management teams in developing transformative therapies for the benefit of patients. Pfizer is an ideal partner to take ReViral’s important mission forward.”